# Dalargin for Prevention of Organ Disfunction in High-Risk Abdominal Surgery

> **NCT07404358** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Botkin Hospital** · enrollment: 200 (actual)

## Conditions studied

- Postoperative Complications
- Multiple Organ Failure
- Abdominal Surgery

## Interventions

- **DRUG:** Dalargin
- **OTHER:** 0.9 % NaCl

## Key facts

- **NCT ID:** NCT07404358
- **Lead sponsor:** Botkin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-13
- **Primary completion:** 2026-07-20
- **Final completion:** 2026-12-20
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07404358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07404358, "Dalargin for Prevention of Organ Disfunction in High-Risk Abdominal Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07404358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*